Wegovy remains in the spotlight as regulatory warnings for rare vision-loss risks surface; its maker faces pushing growth and legal scrutiny amid cost debates.
The FDA has required warning labels on GLP-1 drugs used for obesity and diabetes after reviewing data that link a rare eye condition, NAION, to these medications. The warning covers a dozen drugs, including Ozempic, Wegovy, Mounjaro and Zepbound. Trials and real-world data show NAION occurrences are rare but higher than in non-GLP-1 therapies.
Foundayo, the oral GLP-1 weight-loss pill by Eli Lilly, has been authorised by the MHRA for weight management and type 2 diabetes. It will be available privately; NHS adoption depends on NICE evaluation. Several UK outlets report on uptake, pricing, side effects and competing pills, including Wegovy and Wegovy HD.
Harvey Nichols has been put up for sale after successive losses and is drawing bids from Frasers Group and Next as owners seek £50m–£60m; Mike Ashley has called the chain in a "death spiral" and says a lower price will be needed. Separately, UK high street restructuring plans have won court approval while retailers use AI to trace complex apparel supply chains.
A BBC Business report notes rising use of weight-loss drugs in 2024-25, with a focus on male users and safety concerns, while other outlets explore personal journeys with GLP-1 medications and gut health trends.
New study finds Med-South, a North Carolina adaptation of the Mediterranean diet, helps weight loss and improves diet quality compared with Weight Watchers. Both programs achieve similar weight loss, but Med-South yields higher-quality eating habits through phased support over two years.
UK pharmacies are now able to offer orforglipron (Foundayo), the second GLP-1 pill for weight loss, following MHRA approval. The pill, manufactured by Eli Lilly, is available initially by private prescription while NICE assesses a potential NHS rollout in England. It targets BMI thresholds (30+, or 27-30 with weight-related conditions) and is taken daily with no food or water restrictions.
GLP-1 medications are being increasingly prescribed off-label to children aged 8–11 in the US, despite no FDA approval for under-12s. A NYU Langone study shows a dramatic rise in June 2026, while experts warn about long-term effects and the broader obesity crisis.
A set of weight-loss drugs known as GLP-1s show strong average effectiveness, but a notable minority of patients experience little to no weight loss. Researchers are investigating why responses vary, aiming to tailor treatments and improve cost-effectiveness.
Investors have pushed new biotech winners — from Novo Nordisk’s semaglutide pill to startups tackling baldness and targeted autoimmune drugs — while market enthusiasm has cooled for some forecasts. Novo Nordisk has released a daily weight‑loss pill used by over 1.5 million people; hair‑loss startups have sent small caps soaring; India’s low‑cost GLP‑1 generics have underperformed expectations.
Companies are reviewing coverage for GLP-1 weight-loss drugs as costs rise. Some have already trimmed benefits, while others cite long-term employee health benefits as a reason to maintain or adjust coverage. The trend could raise healthcare costs for employers and influence benefits strategies.
Novo has laid out a plan to diversify beyond Wegovy and Ozempic as it faces looming exclusivity losses. Capital Markets Day signals a push into cardiovascular, liver and blood disorders with a target to expand its pipeline, while investors question credibility and near-term milestones amid a evolving GLP-1 landscape dominated by Lilly.
Lawsuits allege GLP-1 diabetes drugs may cause nonarteritic anterior ischemic optic neuropathy (NAION), an eye condition that can cause permanent vision loss. Novo Nordisk and Eli Lilly dispute the claims as regulators review data; meanwhile trials and studies show mixed signals about risk.
The FDA has required safety labeling for GLP-1 receptor agonists, warning of a potential link to non-arteritic anterior ischemic optic neuropathy (NAION). While NAION is rare, the agency says cases have been reported and risk factors overlap with patients using GLP-1 therapies. Health providers are urged to monitor for painless vision loss and refer promptly to ophthalmology if suspected.